E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020772 |
E.1.2 | Term | Hypertension |
E.1.2 | System Organ Class | 10047065 - Vascular disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effect of ALN-AGT01 on SBP as assessed by ABPM at Month 3 |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives of the study include the following through Month 6: • To evaluate the effect of ALN-AGT01 on blood pressure assessed by ABPM • To evaluate the effect of ALN-AGT01 on office blood pressure • To characterize the PD effects of ALN-AGT01 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age 18 to 75 years - Daytime mean SBP ≥135 mmHg and ≤160 mmHg by ABPM, without antihypertensive medication |
|
E.4 | Principal exclusion criteria |
- Secondary hypertension - Orthostatic hypotension - Elevated potassium >5 mEq/L - eGFR of ≤30 mL/min/1.73m2 - Received an investigational agent within the last 30 days - Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus - History of any cardiovascular event within 6 months prior to randomization - History of intolerance to SC injection(s) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change from baseline at Month (M) 3 in 24-hour mean SBP assessed by ABPM |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Key secondary endpoints: - Change from baseline at M3 in office SBP - Change from baseline at M6 in 24-hour mean SBP assessed by ABPM - Change from baseline at M6 in office SBP - Proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg and/or reduction ≥20 mmHg without additional antihypertensive medications at M6
Other secondary endpoints: - Time-adjusted change from baseline in 24-hour mean SBP and DBP, assessed by ABPM - Change from baseline in 24-hour mean DBP, assessed by ABPM - Change from baseline in office SBP and DBP - Change in serum AGT - Change in daytime and nighttime blood pressure (including dipping pattern) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Key secondary endpoints: - Change from baseline (BL) at M3 in office SBP: BL, M3 - Change from BL at M6 in 24-hour mean SBP assessed by ABPM: BL, M6 - Change from BL at M6 in office SBP: BL, M6 - Proportion of patients with 24-hour mean SBP assessed by ABPM <130 mmHg and/or reduction ≥20 mmHg without additional antihypertensive medications at M6: M6
Other secondary endpoints: - Time-adjusted change from baseline in 24-hour mean SBP and DBP, assessed by ABPM: BL, M1, 3, 6, 7, 9, 12, 24 - Change from BL in 24-hour mean DBP, assessed by ABPM/Change in daytime and nighttime blood pressure: BL, M1, 3, 6, 7, 9, 12, 24 - Change from BL in office SBP and DBP/Change in serum AGT: BL, D1, Week 2, M1, 2, 3, 4, 5, 6, 6.5, 7, 8, 9, 12, 15, 18, 21, 24
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 5 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 18 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
India |
Malaysia |
New Zealand |
United States |
France |
Netherlands |
Germany |
Ukraine |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |